[go: up one dir, main page]

AR063618A1 - Composicion farmaceutica - Google Patents

Composicion farmaceutica

Info

Publication number
AR063618A1
AR063618A1 ARP070104976A ARP070104976A AR063618A1 AR 063618 A1 AR063618 A1 AR 063618A1 AR P070104976 A ARP070104976 A AR P070104976A AR P070104976 A ARP070104976 A AR P070104976A AR 063618 A1 AR063618 A1 AR 063618A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
isoindoline
pentamethyl
absorbability
benzofuran
Prior art date
Application number
ARP070104976A
Other languages
English (en)
Inventor
Satoshi Linuma
Kazhisa Kamikaua
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR063618A1 publication Critical patent/AR063618A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se provee una composición farmacéutica que comprende (1) (R)-5,6-dimetoxi-2-[2,2,4,6,7-pentametil-3-(4-metil-fenil)-2,3-dihidro-1-benzofuran-5-il]isoindolina, ( 2) un componente lipofílico y (3) un agente tensioactivo, que puede proveer en forma estable y suficiente mejoramiento de la absorbabilidad del fármaco sin ser afectado por la cantidad y calidad de una comida.
ARP070104976A 2006-11-09 2007-11-08 Composicion farmaceutica AR063618A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006303800 2006-11-09

Publications (1)

Publication Number Publication Date
AR063618A1 true AR063618A1 (es) 2009-02-04

Family

ID=38942774

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104976A AR063618A1 (es) 2006-11-09 2007-11-08 Composicion farmaceutica

Country Status (11)

Country Link
US (1) US20100273852A1 (es)
EP (1) EP2079455B1 (es)
JP (1) JP2010509188A (es)
AR (1) AR063618A1 (es)
AT (1) ATE456365T1 (es)
CA (1) CA2668864A1 (es)
CL (1) CL2007003217A1 (es)
DE (1) DE602007004642D1 (es)
PE (1) PE20081491A1 (es)
TW (1) TW200833374A (es)
WO (1) WO2008056822A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3291872A4 (en) 2015-05-06 2019-02-13 SynAgile Corporation PHARMACEUTICAL SUSPENSIONS WITH ACTIVE SUBSTANCES, DEVICES FOR THEIR ADMINISTRATION AND METHOD FOR THEIR USE
SG11202007595WA (en) 2018-02-09 2020-09-29 Decibel Therapeutics Inc Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
CN1297550C (zh) * 1998-12-04 2007-01-31 武田药品工业株式会社 苯并呋喃衍生物及其制备和用途
WO2001074331A1 (en) * 2000-04-04 2001-10-11 Shionogi & Co., Ltd. Oily compositions containing highly fat-soluble drugs
CA2432410A1 (en) * 2000-12-28 2002-07-11 Takeda Chemical Industries, Ltd. Process for preparing optically active 2,3-dihydro- benzofuran compounds
EP1457207A4 (en) * 2001-12-19 2008-05-28 Takeda Pharmaceutical SOLID COMPOSITIONS WITH OXYGEN INSTABILITY COMPOUNDS AND STABILIZATION METHOD THEREFOR
US20050148650A1 (en) * 2002-03-01 2005-07-07 Shigenori Ohkawa Antidepressant

Also Published As

Publication number Publication date
EP2079455B1 (en) 2010-01-27
US20100273852A1 (en) 2010-10-28
TW200833374A (en) 2008-08-16
PE20081491A1 (es) 2008-11-12
EP2079455A1 (en) 2009-07-22
CL2007003217A1 (es) 2008-07-04
JP2010509188A (ja) 2010-03-25
ATE456365T1 (de) 2010-02-15
CA2668864A1 (en) 2008-05-15
DE602007004642D1 (de) 2010-03-18
WO2008056822A1 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
EA201070568A1 (ru) Фармацевтические составы
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
MX2009004861A (es) Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa.
EA201290984A1 (ru) Гелеобразные фармацевтические композиции, препятствующие злоупотреблению
BR0015188A (pt) Composições farmacêuticas
WO2004062577A3 (en) Two or more enteric materials to regulate drug release
CY1109719T1 (el) Σκευασμα 1-[(3-υδροξυ-αδαμαντ-1-υλαμινο)-ακετυλο]-πυρρολιδινο-2-(s)-καρβονιτριλιου τροποποιημενης απελευθερωσης
UY31647A1 (es) Forma de dosificación farmacéutica para la administración oral de inhibidor de tirosina quinasa
CY1113462T1 (el) Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο
ECSP088239A (es) Composición de liberación de fármaco sostenida
MA30765B1 (fr) Derives innovants du thiophene
AR045352A1 (es) Forma de dosificacion a prueba de abuso
AR062860A1 (es) Combinaciones terapeuticas 482
EA200801926A1 (ru) Таблетки парацетамола с быстрым высвобождением
WO2007062078A3 (en) Thrombopoietin activity modulating compounds and methods
MX2009010289A (es) Composiciones para administracion nasal.
ATE555777T1 (de) Pharmazeutische zusammensetzung
PA8586201A1 (es) Nuevas formulaciones de liberacion prolongada inyectables
MA33463B1 (fr) Compositions à dose pharmaceutique solide fixe comprenant de l'irbésartan et de l'amlodipine, leur préparation et leur application thérapeutique
CR9632A (es) Tableta que contiene un ingrediente dificilmente soluble
CL2009000980A1 (es) Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006).
CY1115955T1 (el) Ενα στερεο φαρμακευτικο σκευασμα
AR063618A1 (es) Composicion farmaceutica
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).
CR8371A (es) Formulaciones de medicamento que contienen saborizantes con mejores propiedades farmaceuticas

Legal Events

Date Code Title Description
FB Suspension of granting procedure